NCT04121260View on ClinicalTrials.gov

A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 25, 2019

Primary Completion Date

April 27, 2021

Study Completion Date

October 13, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab

Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.

Trial Locations (5)

100191

Peking University Third Hospital, Beijing

210009

Zhongda Hospital,Southeast University, Nanjing

300320

Institute of Hematology & Blood Diseases Hospital, Tianjin

410013

The Third Xiangya Hospital, Central South University, Changsha

510515

Nanfang Hospital, Guangzhou

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04121260 - A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma | Biotech Hunter | Biotech Hunter